Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence:: a systematic review

被引:351
作者
Carmen, B [1 ]
Angeles, M [1 ]
Ana, M [1 ]
María, AJ [1 ]
机构
[1] Inst Salud Carlos 3, Agcy Hlth Technol Assessment, Madrid 28029, Spain
关键词
acamprosate; alcohol dependence; alcoholism treatment; meta-analysis; naltrexone;
D O I
10.1111/j.1360-0443.2004.00763.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence. Methods Systematic review of the literature (1990-2002) and meta-analysis of full published randomized and controlled clinical trials assessing acamprosate or naltrexone therapy in alcohol dependence. Estimates of effect were calculated according to the fixed-effects model. Measurements Relapse and abstinence rates, cumulative abstinence duration and treatment compliance were considered as primary outcomes. Findings Thirty-three studies met the inclusion criteria. Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1.88 (1.57, 2.25), P < 0.001] and days of cumulative abstinence [WMD: 26.55 (17.56, 36.54]. Short-term administration of naltrexone reduced the relapse rate significantly [OR: 0.62 (0.52, 0.75),P<0.001], but was not associated with a significant modification in the abstinence rate [OR: 1.26 (0.97, 1.64), P = 0.08]. There were insufficient data to ascertain naltrexone's efficacy over more prolonged periods. Acamprosate had a good safety pattern and was associated with a significant improvement in treatment compliance [OR: 1.29 (L 13, 1.47), P<0.001]. Naltrexone's side effects were more numerous, yet the drug was nevertheless tolerated acceptably without being associated with a lower adherence to treatment (OR: 0.94 (0.80, 1.1), P = 0.5). However, overall compliance was relatively low with both medications. Conclusions Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults. Acamprosate appears to be especially useful in a therapeutic approach targeted at achieving abstinence, whereas naltrexone seems more indicated in programmes geared to controlled consumption. Both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice.
引用
收藏
页码:811 / 828
页数:18
相关论文
共 50 条
  • [21] Naltrexone in the treatment of alcohol dependence
    Mangado, EO
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2000, 28 (08): : 37 - 43
  • [22] Naltrexone in the treatment of alcohol dependence
    Mangado, EO
    ACTAS LUSO-ESPANOLAS DE NEUROLOGIA PSIQUIATRIA Y CIENCIAS AFINES, 1998, 26 (01): : 51 - 57
  • [23] Acamprosate: A Review of Its Use in Alcohol Dependence
    Greg L. Plosker
    Drugs, 2015, 75 : 1255 - 1268
  • [24] Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
    Witkiewitz, Katie
    Saville, Kimber
    Hamreus, Kacie
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 45 - 53
  • [25] Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
    Mason, Barbara J.
    Heyser, Charles J.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (01) : 23 - 32
  • [26] Efficacy of naltrexone in the treatment of alcohol dependence disorder in women
    Ponce, G
    Sánchez-García, J
    Rubio, G
    Rodríguez-Jiménez, R
    Jiménez-Arriero, MAJ
    Palomo, T
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2005, 33 (01): : 13 - 18
  • [27] Efficacy and Tolerability of Naltrexone in the Management of Alcohol Dependence
    Garbutt, James C.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (19) : 2091 - 2097
  • [28] Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial
    Morley, Kirsten C.
    Teesson, Maree
    Reid, Sophie C.
    Sannibale, Claudia
    Thomson, Clare
    Phung, Nghi
    Weltman, Martin
    Bell, James R.
    Richardson, Kylie
    Haber, Paul S.
    ADDICTION, 2006, 101 (10) : 1451 - 1462
  • [29] Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence
    Frye, Mark A.
    Hinton, David J.
    Karpyak, Victor M.
    Biernacka, Joanna M.
    Gunderson, Lee J.
    Feeder, Scott E.
    Choi, Doo-Sup
    Port, John D.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) : 669 - 674
  • [30] Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
    Ralevski, Elizabeth
    O'Brien, Erin
    Jane, J. Serrita
    Dwan, Rita
    Dean, Erica
    Edens, Ellen
    Arnaout, Bachaar
    Keegan, Kathryn
    Drew, Shannon
    Petrakis, Ismene
    JOURNAL OF DUAL DIAGNOSIS, 2011, 7 (1-2) : 64 - 73